.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Harvard Business School
McKesson
US Department of Justice
Mallinckrodt
Queensland Health
Accenture
Argus Health
Covington
Medtronic

Generated: November 19, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,828,427

« Back to Dashboard

Which drugs does patent 8,828,427 protect, and when does it expire?


Patent 8,828,427 protects POMALYST and is included in one NDA. There has been one Paragraph IV challenge on Pomalyst.

This patent has thirty-two patent family members in twenty-nine countries.

Summary for Patent: 8,828,427

Title:Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
Abstract: Pharmaceutical compositions and single unit dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, or a pharmaceutically acceptable stereoisomer, prodrug, salt, solvate, hydrate, or clathrate, are provided herein. Also provided are methods of treating, managing, or preventing various disorders, such as cancer or an inflammatory disease.
Inventor(s): Tutino; Anthony (New Providence, NJ), Kelly; Michael T. (Lake Hopatcong, OH)
Assignee: Celgene Corporation (Summit, NJ)
Application Number:12/783,390
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Celgene
POMALYST
pomalidomide
CAPSULE;ORAL204026-001Feb 8, 2013RXYesNo► Subscribe► SubscribeYY
Celgene
POMALYST
pomalidomide
CAPSULE;ORAL204026-002Feb 8, 2013RXYesNo► Subscribe► SubscribeYY
Celgene
POMALYST
pomalidomide
CAPSULE;ORAL204026-003Feb 8, 2013RXYesNo► Subscribe► SubscribeYY
Celgene
POMALYST
pomalidomide
CAPSULE;ORAL204026-004Feb 8, 2013RXYesYes► Subscribe► SubscribeYY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,828,427

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Poland2391355► Subscribe
Philippines12015501523► Subscribe
Peru06542012► Subscribe
New Zealand594557► Subscribe
Mexico2011008554► Subscribe
Mexico342330► Subscribe
Lithuania2391355► Subscribe
South Korea101381060► Subscribe
South Korea20120014114► Subscribe
Japan5752677► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
US Army
Merck
Fuji
Medtronic
Accenture
Deloitte
Julphar
Chinese Patent Office
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot